1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

por Corey, Ralph, Wikler, Matthew, Moeck, Greg, Jiang, Hai, Good, Samantha
Publicado 2014

1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Nega...

por Avery, Lindsay M, Vernacchio, Salvador, McLaughlin, Lisa, Xerri, Luigi, Moeck, Greg, Pevear, Daniel
Publicado 2020

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program

por Redell, Mark, Moeck, Greg, Lucasti, Christopher, Durso, Stephanie, Kennedy, Cynthia, Fusaro, Karen, Loutit, Jeff, Dudley, Michael
Publicado 2018

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance...

por Karlowsky, James A., Wise, Mark G., Hackel, Meredith A., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Publicado 2022

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)

por Dorr, Mary Beth, Gasink, Leanne, Henkel, Tim, Moeck, Greg, Chen, Hongzi, McConnell, Scott A, McGovern, Paul
Publicado 2023

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

por McGovern, Paul C, Wagenlehner, Florian, Gasink, Leanne, Moeck, Greg, McLeroth, Patrick L, Beth, Mary, Dane, Aaron, Henkel, Tim
Publicado 2022

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

por Mojica, Maria F., Zeiser, Elise T., Becka, Scott A., LiPuma, John J., Six, David A., Moeck, Greg, Papp-Wallace, Krisztina M.
Publicado 2023

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study

por Moeck, Greg, Gasink, Leanne, Dorr, Mary Beth, Chen, Hongzi, Woosley, Leah, Mendes, Rodrigo E, Wagenlehner, Florian, Henkel, Tim, McGovern, Paul
Publicado 2023

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobia...

por Karlowsky, James A., Hackel, Meredith A., Wise, Mark G., Six, David A., Uehara, Tsuyoshi, Daigle, Denis M., Cusick, Susan M., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Publicado 2022

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam

por Mack, Andrew R, Bethel, Christopher, Marshall, Steven, Patel, Robin, Patel, Robin, van Duin, David, Fowler, Vance G, Rhoads, Daniel D, Jacobs, Michael, van den Akker, Focco, Six, David A, Moeck, Greg, Papp-Wallace, Krisztina M, Bonomo, Robert A
Publicado 2021

133. ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam

por Mack, Andrew R, Bethel, Christopher, Marshall, Steven, Patel, Robin, Patel, Robin, van Duin, David, Fowler, Vance G, Rhoads, Daniel D, Jacobs, Michael, van den Akker, Focco, Six, David A, Moeck, Greg, Papp-Wallace, Krisztina M, Bonomo, Robert A
Publicado 2021

1055. ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236

por Mack, Andrew R, Bethel, Christopher, Marshall, Steven, Patel, Robin, Patel, Robin, van Duin, David, Fowler, Vance G, Rhoads, Daniel D, Jacobs, Michael, van den Akker, Focco, Six, David A, Moeck, Greg, Papp-Wallace, Krisztina M, Bonomo, Robert A
Publicado 2021

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

por Trout, Robert E., Zulli, Allison, Mesaros, Eugen, Jackson, Randy W., Boyd, Steven, Liu, Bin, Hamrick, Jodie, Daigle, Denis, Chatwin, Cassandra L., John, Kaitlyn, McLaughlin, Lisa, Cusick, Susan M., Weiss, William J., Pulse, Mark E., Pevear, Daniel C., Moeck, Greg, Xerri, Luigi, Burns, Christopher J.
Publicado 2021

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

por Hamrick, Jodie C., Docquier, Jean-Denis, Uehara, Tsuyoshi, Myers, Cullen L., Six, David A., Chatwin, Cassandra L., John, Kaitlyn J., Vernacchio, Salvador F., Cusick, Susan M., Trout, Robert E. L., Pozzi, Cecilia, De Luca, Filomena, Benvenuti, Manuela, Mangani, Stefano, Liu, Bin, Jackson, Randy W., Moeck, Greg, Xerri, Luigi, Burns, Christopher J., Pevear, Daniel C., Daigle, Denis M.
Publicado 2020